Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings.
ADC
Trop-2
bystander effect
target therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Mar 2023
13 Mar 2023
Historique:
received:
09
01
2023
revised:
05
03
2023
accepted:
09
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
Trophoblast cell surface antigen-2 (Trop-2) is a glycoprotein that was first described as a membrane marker of trophoblast cells and was associated with regenerative abilities. Trop-2 overexpression was also described in several tumour types. Nevertheless, the therapeutic potential of Trop-2 was widely recognized and clinical studies with drug-antibody conjugates have been initiated in various cancer types. Recently, these efforts have been rewarded with the approval of sacituzumab govitecan from both the Food and Drug Administration (FDA) and European Medicines Agency (EMA), for metastatic triple-negative breast cancer patients. In our work, we briefly summarize the various characteristics of cancer cells overexpressing Trop-2, the pre-clinical activities of specific inhibitors, and the role of anti-Trop-2 therapy in current clinical practice. We also review the ongoing clinical trials to provide a snapshot of the future developments of these therapies.
Identifiants
pubmed: 36980630
pii: cancers15061744
doi: 10.3390/cancers15061744
pmc: PMC10046386
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Gilead Sciences (Italy)
ID : NA
Références
BMC Cancer. 2017 Jul 14;17(1):486
pubmed: 28709407
Genes Cancer. 2015 Mar;6(3-4):84-105
pubmed: 26000093
J Clin Pathol. 2009 Feb;62(2):152-8
pubmed: 18930986
Development. 2009 Jun;136(11):1951-60
pubmed: 19429791
J Med Chem. 2014 Dec 26;57(24):10527-43
pubmed: 25431858
Mol Cancer Ther. 2016 Nov;15(11):2698-2708
pubmed: 27582525
Mol Cancer Res. 2011 Dec;9(12):1686-95
pubmed: 21970857
Proc Natl Acad Sci U S A. 1981 Aug;78(8):5147-50
pubmed: 7029529
Proc Natl Acad Sci U S A. 1990 Sep;87(17):6833-7
pubmed: 2395876
Clin Cancer Res. 2015 Nov 15;21(22):5131-8
pubmed: 26106073
J Histochem Cytochem. 2011 Jul;59(7):701-10
pubmed: 21551320
J Clin Oncol. 2017 Aug 20;35(24):2790-2797
pubmed: 28548889
Proteins. 1999 May 15;35(3):360-3
pubmed: 10328271
Clin Cancer Res. 2016 Aug 15;22(16):4197-205
pubmed: 27022065
Dev Dyn. 2006 Jun;235(6):1578-88
pubmed: 16552761
Cancer Manag Res. 2017 Dec 12;9:821-837
pubmed: 29276405
Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):861-870
pubmed: 34519889
Dev Dyn. 2015 Feb;244(2):99-109
pubmed: 25523132
Oncotarget. 2015 Jun 10;6(16):14318-28
pubmed: 26015409
Oncogene. 2013 Mar 21;32(12):1594-600
pubmed: 22562244
Invest New Drugs. 2018 Oct;36(5):836-847
pubmed: 29333575
Cancers (Basel). 2020 Nov 11;12(11):
pubmed: 33187148
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20111-6
pubmed: 24282295
Eur Urol Oncol. 2022 Dec;5(6):714-718
pubmed: 35216942
Clin Cancer Res. 2015 Sep 1;21(17):3870-8
pubmed: 25944802
Mol Cancer Ther. 2008 Feb;7(2):280-5
pubmed: 18281513
Oncotarget. 2018 Jun 22;9(48):28989-29006
pubmed: 29989029
PLoS One. 2013 Sep 27;8(9):e75864
pubmed: 24086649
Sci Rep. 2015 Oct 21;5:15437
pubmed: 26486755
Clin Cancer Res. 2017 Oct 1;23(19):5711-5719
pubmed: 28679770
Science. 2010 Jul 30;329(5991):568-71
pubmed: 20671189
Exp Ther Med. 2017 Sep;14(3):1947-1952
pubmed: 28962108
Clin Cancer Res. 2011 May 15;17(10):3157-69
pubmed: 21372224
Oncogene. 2014 Feb 6;33(6):702-12
pubmed: 23416980
Oncogene. 2013 Jan 10;32(2):222-33
pubmed: 22349828
Int J Cancer. 1995 Aug 9;62(4):472-9
pubmed: 7635574
Oncotarget. 2017 Jul 18;8(29):47052-47063
pubmed: 28423362
Biochim Biophys Acta. 2009 Dec;1796(2):309-14
pubmed: 19683559
Mol Imaging Biol. 2015 Feb;17(1):94-101
pubmed: 25060065
EMBO Mol Med. 2012 Jun;4(6):472-85
pubmed: 22419550
ScientificWorldJournal. 2010 Oct 12;10:2070-89
pubmed: 20953556
Mol Cell Biol. 1993 Mar;13(3):1507-15
pubmed: 8382772
Mol Cancer Ther. 2021 Dec;20(12):2329-2340
pubmed: 34413126
Protein Expr Purif. 2013 Sep;91(1):69-76
pubmed: 23872121
Clin Cancer Res. 2005 Jun 15;11(12):4357-64
pubmed: 15958618
J Nucl Med. 2012 Oct;53(10):1625-32
pubmed: 22952342
Int J Cancer. 1987 Mar 15;39(3):297-303
pubmed: 2434438
J Clin Oncol. 2022 Oct 10;40(29):3365-3376
pubmed: 36027558
Hum Mol Genet. 2000 Apr 12;9(6):1001-7
pubmed: 10767324
Ann Oncol. 2020 Dec;31(12):1709-1718
pubmed: 32946924
Oncol Lett. 2018 Mar;15(3):3820-3827
pubmed: 29467899
Exp Ther Med. 2015 Aug;10(2):429-434
pubmed: 26622333
Cancer Res. 2013 May 15;73(10):3155-67
pubmed: 23536555
Exp Mol Pathol. 2013 Feb;94(1):73-8
pubmed: 23031786
J Clin Oncol. 2021 Aug 1;39(22):2474-2485
pubmed: 33929895
Ann Oncol. 2021 Jun;32(6):746-756
pubmed: 33741442
Cancer Lett. 2007 Oct 8;255(2):232-40
pubmed: 17553616
Sci Rep. 2016 Sep 20;6:33658
pubmed: 27645103
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20882-7
pubmed: 19088204
Bioconjug Chem. 2015 May 20;26(5):919-31
pubmed: 25915780
Int J Cancer. 1998 May 29;76(5):671-6
pubmed: 9610724
Int J Cancer. 1998 Jan 19;75(2):324-30
pubmed: 9462726
Mol Cancer. 2010 Sep 21;9:253
pubmed: 20858281
Oncotarget. 2015 Sep 8;6(26):22496-512
pubmed: 26101915
Cancer Med. 2017 May;6(5):994-1001
pubmed: 28256068
BMC Clin Pathol. 2012 Nov 14;12:22
pubmed: 23151048
Oncotarget. 2014 Oct 15;5(19):9281-94
pubmed: 25238142
J Cell Physiol. 2012 Nov;227(11):3670-7
pubmed: 22378065
Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4482-7
pubmed: 27044116
Histol Histopathol. 2009 Aug;24(8):1035-48
pubmed: 19554511
Anticancer Drugs. 2007 Apr;18(4):419-25
pubmed: 17351394
Proc Natl Acad Sci U S A. 2010 Oct 5;107(40):17298-303
pubmed: 20855612
N Engl J Med. 2021 Apr 22;384(16):1529-1541
pubmed: 33882206
J Clin Oncol. 2017 Jul 1;35(19):2141-2148
pubmed: 28291390